Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


39th World Cancer Conference

Rome, Italy

Assel Issabekova

Assel Issabekova

National Center for Biotechnology, Kazakhstan

Title: In vitro study of the immunostimulating potential of dendritic vaccines and the cytotoxic activity of human CIK cells


Biography: Assel Issabekova


Adoptive cell therapy is the promising strategy in cancer immunotherapy. We studied the effect of human dendritic cells (DCs) treated with antigens of the colorectal tumor cell line SW-620 on the cytotoxic activity of human cytokine-induced killer (CIK) cells. Immunogenic apoptotic cells, lysates and total RNAs of tumor were obtained by various methods, including the exposure of SW-620 to various chemotherapy drugs (staurosporine, oxaliplatin, mitoxantrone, 5-fluorouracil). All tumor cells were preliminarily subjected to heat shock. Effect of DC was investigated on ex vivo expanded CD56+ CIK cells of whole blood or blood mononuclear cells. Antigen-loaded DCs were cultured with CD56+ CIK cells at a 10:1 ratio for 48 hours. Cytotoxicity was assessed by MTT-assay using SW-620 cells as targets. In accordance with results the highest lytic activity was found in the group with CIK cells of total blood activated by Mo-DC, loaded with oxaliplatin, staurosporine -induced apoptotic tumor cells, total tumor RNA, and tumor lysates. Comparison of the activation potential of T-lymphocytes revealed that CIK cells of whole blood have a higher cytotoxicity compared to CIK cells of peripheral blood mononuclear cells. Additional stimulation of DC maturation by TNF-α enhances the cytotoxic activity of CIK cell.

Supported by a grant AP05135467 "Development of production technology of dendritic vaccines and cytokine-induced killer cells for combination therapy in colorectal cancer" from the MES RK.